ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 338

Bombina Variegate peptide8/Prokineticin 2: A Novel Arthritis-Inducible Chemokine

Haruyasu Ito, Ken Yoshida, Kentaro Noda and Daitaro Kurosaka, Internal Medicine, Jikei University School of Medicine, Tokyo, Japan

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: animal models and rheumatoid arthritis, chemokines, pathogenesis, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Animal Models

Session Type: Abstract Submissions (ACR)

Background/Purpose

Rheumatoid arthritis (RA) is a chronic inflammatory disorder characterized by the joint destruction. Chemokines play important roles as monocyte and neutrophil recruiters in RA. Bombina variegate peptide 8 (Bv8), one of such chemokines is highly expressed in various tissues including the brain, testis, and bone marrow. Bv8 has a diversity of functions, being involved in angiogenesis, neurogenesis, circadian rhythm, and pain threshold. We have previously reported that Bv8 expression level was elevated in the synovial tissue of collagen induced arthritis (CIA) mice.  However, it is still unknown whether Bv8 can induce arthritis. Therefore, in this study, we investigated the expressions of Bv8 and its receptors (PKR1, PKR2) in CIA mice. And, we also examined whether Bv8 recruits polymorphonuclear neutrophils (PMNs) and monocytes in vitro and induces inflammatory arthritis in vivo. 

Methods

CIA was induced in 6-week-old DBA/1j male mice. PKR1 and PKR2 mRNA expression levels of joints in CIA mice were measured by real-time PCR on days 28 and 35 and compared to those in normal mice. Immunohistochemical (IHC) staining was performed to semi-quantitate PKR1 or PKR2 expression on day 28 in the synovial tissue. We performed monocyte and neutrophil chemotaxis assays in response to recombinant Bv8 (rBv8) using Boyden chambers. Resuls were expressed as the fold increase of the number of migrated cells compared to PBS. To test Bv8 for inflammatory activity in vivo, we injected PBS or rBv8 (10-10M, 20μl) into knee joints. The knee circumference measurements were taken in a blinded manner before and 24 hours after the intraarticular injection for all mice. IHC stainings for PMNs (Gr-1/Ly6G) and monocytes (F4/80) were performed on paraffin sections from mouse knee joints to quantify Gr-1/Ly6G and F4/80 positive cells in the Bv8 group compared to the PBS group, respectively. 

Results

In the CIA group, PKR1 mRNA expression level was significantly higher on days 35 than the control group (p<0.05), and PKR2 mRNA expression level was significantly higher on days 28 and 35 than the control group (p<0.05). IHC stainings for PKR1 and PKR2 both showed significantly higher expressions of receptors in synovial tissue in the CIA group compared to the control group. PMN chemotaxis assays showed that rBv8 had significantly increased PMN chemotactic activity at 10-12 M compared to PBS (p<0.05). Joints injected with rBv8 had significantly increased knee circumference than those injected with PBS (p<0.05). The number of Gr-1/Ly6G positive cells was significantly higher in mouse knee joints injected with rBv8 compared to PBS (p<0.05). There was no significant difference in the number of F4/80 positive cells in both groups. 

Conclusion

As well as Bv8, PKR1 and PKR2 expression levels were elevated in the synovial tissue of the CIA group. Bv8 recruited PMNs in vitro and induced neutrophil-driven inflammatory arthritis. These results indicate that Bv8 may have a previously unrecognized pathogenesis in RA by recruiting neutrophils. Targeting Bv8 may provide a new therapeutic strategy to treat inflammatory arthritis.


Disclosure:

H. Ito,
None;

K. Yoshida,
None;

K. Noda,
None;

D. Kurosaka,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/bombina-variegate-peptide8prokineticin-2-a-novel-arthritis-inducible-chemokine/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology